These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11590670)

  • 1. Towards a human Lassa fever vaccine.
    Fisher-Hoch SP; McCormick JB
    Rev Med Virol; 2001; 11(5):331-41. PubMed ID: 11590670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
    Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
    mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
    Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
    Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
    Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.
    Zapata JC; Poonia B; Bryant J; Davis H; Ateh E; George L; Crasta O; Zhang Y; Slezak T; Jaing C; Pauza CD; Goicochea M; Moshkoff D; Lukashevich IS; Salvato MS
    Virol J; 2013 Feb; 10():52. PubMed ID: 23402317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.
    Clegg JC; Lloyd G
    Lancet; 1987 Jul; 2(8552):186-8. PubMed ID: 2885642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
    Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective vaccine for lassa fever.
    Fisher-Hoch SP; Hutwagner L; Brown B; McCormick JB
    J Virol; 2000 Aug; 74(15):6777-83. PubMed ID: 10888616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Klena JD; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2018 May; 217(12):1957-1966. PubMed ID: 29800368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
    mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.
    Zapata JC; Goicochea M; Nadai Y; Eyzaguirre LM; Carr JK; Tallon LJ; Sadzewicz L; Myers G; Fraser CM; Su Q; Djavani M; Lukashevich IS; Salvato MS
    J Virol; 2014 Mar; 88(6):3058-66. PubMed ID: 24335292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lassa fever: implications of T-cell immunity for vaccine development.
    ter Meulen J
    J Biotechnol; 1999 Aug; 73(2-3):207-12. PubMed ID: 10486929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine platforms to control Lassa fever.
    Lukashevich IS; Pushko P
    Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lassa fever vaccine.
    Fisher-Hoch SP; McCormick JB
    Expert Rev Vaccines; 2004 Apr; 3(2):189-97. PubMed ID: 15056044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a new vaccine for the prevention of Lassa fever.
    Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
    PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
    Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
    Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
    Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
    Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
    Carrion R; Patterson JL; Johnson C; Gonzales M; Moreira CR; Ticer A; Brasky K; Hubbard GB; Moshkoff D; Zapata J; Salvato MS; Lukashevich IS
    Vaccine; 2007 May; 25(20):4093-102. PubMed ID: 17360080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine platforms for the prevention of Lassa fever.
    Purushotham J; Lambe T; Gilbert SC
    Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.